Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity: MEDIBANK PRIVATE LIMITED |  |
|--|--|
| ABN: 47 080 890 259                      |  |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director    | Craig Drummond   |
|---------------------|------------------|
| Date of last notice | 22 November 2019 |

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest   | Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan ('Performance Rights Plan'))   |
|---|--|
| Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest. |  |
| Date of change  | 28 November 2019   |
| No. of securities held prior to change  | 1,621,404 Performance Rights   |
| Class   | Performance Rights   |
| Number acquired   | <ul> <li>867,432 Performance Rights, comprising:</li> <li>202,404 Performance Rights being the FY19 Deferred Short Term Incentive; and</li> <li>665,028 Performance Rights being the FY20 Long Term Incentive</li> </ul> |
| Number disposed   | Nil  |
| Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation  | Performance Rights granted at nil consideration under the terms of the Performance Rights Plan   |
| No. of securities held after change   | 2,488,836 Performance Rights   |

| Nature of change   | Grant of Performance Rights under the   |
|--|---|
| Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Performance Rights Plan, being the FY19 Deferred Short Term Incentive and FY20 Long |
|  | Term Incentive.   |
|  | Term meentive.  |
|  |   |

| Direct or indirect interest  | Direct and indirect   |
|--|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.                       | Beneficial interest in Medibank Private Limited<br>Ordinary Shares ('Ordinary Shares') held via<br>INVIA Custodian Pty Limited on behalf of B &<br>C Drummond |
| Date of change   | N/A   |
| No. of securities held prior to change   | 732,578 Ordinary Shares   |
| Class  | Ordinary Shares   |
| Number acquired  | N/A   |
| Number disposed  | N/A   |
| Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation   | N/A   |
| No. of securities held after change  | 732,578 Ordinary Shares   |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback | N/A   |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract   | N/A |
|--|-----|
| Nature of interest   | N/A |
| Name of registered holder (if issued securities)   | N/A |
| Date of change   | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired  | N/A |
| Interest disposed  | N/A |
| Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation  | N/A |
| Interest after change  | N/A |

### Part 3 – +Closed period

| Were the interests in the securities or contracts   | No  |
|---|-----|
| detailed above traded during a <sup>+</sup> closed period where prior written clearance was required? |     |
| If so, was prior written clearance provided to allow the trade to proceed during this period?         | N/A |
| If prior written clearance was provided, on what date was this provided?                              | N/A |